Immunoinformatics design of multivalent chimeric vaccine for modulation of the immune system in Pseudomonas aeruginosa infection.


Journal

Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
ISSN: 1567-7257
Titre abrégé: Infect Genet Evol
Pays: Netherlands
ID NLM: 101084138

Informations de publication

Date de publication:
11 2020
Historique:
received: 29 04 2020
revised: 20 06 2020
accepted: 11 07 2020
pubmed: 20 7 2020
medline: 26 10 2021
entrez: 20 7 2020
Statut: ppublish

Résumé

Increasing in drug-resistant Pseudomonas aeruginosa and high mortality and morbidity rate have become a health challenge worldwide; therefore, developing the novel therapeutic strategies such as immunogenic vaccine candidate are required. Despite a substantial research effort, the future of immunization against P. aeruginosa due to failure in covering two separate stages of infection, and furthermore, inducing ineffective type of immune response, still remains controversial. In this study, immunoinformatics approach was utilized to design multivalent chimeric vaccine from both stages of infection containing Lectin, HIV TAT peptide, N-terminal fragment of exotoxin A and Epi8 of outer membrane protein F (OprF) with hydrophobic linkers which have a high density of B-cell, T Lymphocytes (HTL), T Lymphocytes (CTL), and IFN-γ epitopes. The physicochemical properties, antigenicity, and allergenicity for designed vaccine were analyzed. 3D model generation and refinement further validation of the final vaccine were followed by computational docking with molecular dynamics analyses that demonstrated high- affinity interaction between vaccine and TLR-4. Finally, designed vaccine was in silico cloned in pET22b. We have expected that the designed vaccine able to elucidate innate, humoral and cellular innate immune responses and control the interaction of P. aeruginosa with host and maybe overcome to P. aeruginosa vaccines drawback.

Identifiants

pubmed: 32682863
pii: S1567-1348(20)30293-8
doi: 10.1016/j.meegid.2020.104462
pii:
doi:

Substances chimiques

Bacterial Proteins 0
Epitopes, B-Lymphocyte 0
Epitopes, T-Lymphocyte 0
IFNG protein, human 0
OmpF protein 0
Porins 0
Recombinant Fusion Proteins 0
Toll-Like Receptor 4 0
Vaccines, Combined 0
Vaccines, Subunit 0
Interferon-gamma 82115-62-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104462

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Sargol Aminnezhad (S)

Department of Microbiology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran.

Ahya Abdi-Ali (A)

Department of Microbiology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran. Electronic address: abdialya@alzahra.ac.ir.

Tooba Ghazanfari (T)

Immunoregulation Research Center, Shahed University, Tehran, Iran. Electronic address: ghazanfari@shahed.ac.ir.

Mojgan Bandehpour (M)

Cellular and Molecular Biology Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Mahboobe Zarrabi (M)

Department of Biotechnology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH